Evidence map›Paper›PMID 33068226›Full record

ArticleCardiovascular drugs and therapy2021

Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry.

Pieter Vynckier, Giulia Ferrannini, Lars Rydén, Lale Tokgözoğlu, Jan Bruthans, Kornelia Kotseva, David Wood, Tine De Backer, Sofie Gevaert, Dirk De Bacquer and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 6 countries.

Pieter VynckierDepartment of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Pieter.Vynckier@Ugent.be.ORCID 0000-0001-8410-6328
Giulia FerranniniCardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
Lars RydénCardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
Lale TokgözoğluDepartment of Cardiology, Hacettepe University, Ankara, Turkey.
Jan BruthansCentre for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic.
Kornelia KotsevaNational Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland.
David WoodNational Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland.
Tine De BackerDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Sofie GevaertDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Dirk De BacquerDepartment of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Delphine De SmedtDepartment of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
EUROASPIRE V Investigators group
Ghent University · BEGhent University Hospital · BEKarolinska Institutet · SEOllscoil na Gaillimhe – University of Galway · IECharles University · CZHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD).

methodsAnalyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected.

resultsData was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs.

conclusionThe EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.

Indexed as

Cardiovascular AgentsCoronary DiseaseCardiac RehabilitationCoronary Artery BypassEuropeFemaleHealth Knowledge, Attitudes, PracticeHospitalizationHumansMaleMiddle AgedPatient Care ManagementPractice Patterns, Physicians'Secondary PreventionSex FactorsWomen's HealthCardiovascular AgentsCardiovascular diseasesEUROASPIREGenderMedical treatment

Identifiers

PMID33068226
OpenAlexW3092723523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.